Format

Send to

Choose Destination
Haematologica. 2019 May 23. pii: haematol.2018.213314. doi: 10.3324/haematol.2018.213314. [Epub ahead of print]

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma.

Author information

1
Dept. of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam.
2
Dept. of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, New York, USA.
3
Dept.Otolaryngology-Head and Neck Surgery, Amsterdam UMC, VU University Medical Center,Cancer Center.
4
Aarhus University, Aarhus University Hospital, Aarhus, Denmark.
5
Kuros Biosciences BV, Bilthoven, The Netherlands.
6
Kuros Biosciences BV, Bilthoven and Queen Mary University of London.
7
Dept. of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam; t.mutis@vumc.nl.

KEYWORDS:

Bone Marrow Microenvironment; Drug resistance; FL118; Multiple Myeloma; Survivin inhibitor

PMID:
31123033
DOI:
10.3324/haematol.2018.213314
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center